scholarly journals PD-1 Deficiency Enhances Humoral Immunity of Malaria Infection Treatment Vaccine

2015 ◽  
Vol 83 (5) ◽  
pp. 2011-2017 ◽  
Author(s):  
Taiping Liu ◽  
Xiao Lu ◽  
Chenghao Zhao ◽  
Xiaolan Fu ◽  
Tingting Zhao ◽  
...  

Malaria infection treatment vaccine (ITV) is a promising strategy to induce homologous and heterologous protective immunity against the blood stage of the parasite. However, the underlying mechanism of protection remains largely unknown. Here, we found that a malaria-specific antibody (Ab) could mediate the protective immunity of ITV-immunized mice. Interestingly, PD-1 deficiency greatly elevated the levels of both malaria-specific total IgG and subclass IgG2a and enhanced the protective efficacy of ITV-immunized mice against the blood-stage challenge. A serum adoptive-transfer assay demonstrated that the increased Ab level contributed to the enhanced protective efficacy of the immunized PD-1-deficient mice. Further study showed that PD-1 deficiency could also promote the expansion of germinal center (GC) B cells and malaria parasite-specific TFHcells in the spleens of ITV-immunized mice. These results suggest that PD-1 deficiency improves the protective efficacy of ITV-immunized mice by promoting the generation of malaria parasite-specific Ab and the expansion of GC B cells. The results of this study provide new evidence to support the negative function of PD-1 on humoral immunity and will guide the design of a more effective malaria vaccine.

2021 ◽  
Author(s):  
Leetah Senkpeil ◽  
Jyoti Bhardwaj ◽  
Morgan Little ◽  
Prasida Holla ◽  
Aditi Upadhye ◽  
...  

Baseline innate immune signatures can influence protective immunity following vaccination. Here, we used systems transcriptional analysis to assess the molecular mechanisms underlying differential immunogenicity and protective efficacy results of a clinical trial of the radiation-attenuated whole sporozoite PfSPZ Vaccine in African infants. Innate immune activation and myeloid signatures at pre-vaccination baseline correlated with protection from Plasmodium falciparum infection in placebo controls, while the same signatures predicted susceptibility to infection among infants who received the highest and most protective dose of the PfSPZ Vaccine. Machine learning identified monocytes and an antigen presentation signature as pre-vaccination features predictive of malaria infection after highest-dose PfSPZ vaccination. Consistent with these human data, innate stimulation in vivo conferred protection against malaria infection in mice while diminishing the CD8+ T cell response to radiation-attenuated sporozoites. These data establish a dichotomous role of innate stimulation for malaria protection and induction of protective immunity of whole-sporozoite malaria vaccines.


Author(s):  
James G Kublin ◽  
Sean C Murphy ◽  
Janine Maenza ◽  
Annette M Seilie ◽  
Jay Prakash Jain ◽  
...  

Abstract Background KAF156 is a novel antimalarial drug that is active against both liver- and blood-stage Plasmodium parasites, including drug-resistant strains. Here, we investigated the causal prophylactic efficacy of KAF156 in a controlled human malaria infection (CHMI) model. Methods In part 1, healthy, malaria-naive participants received 800 mg KAF156 or placebo 3 hours before CHMI with P. falciparum–infected mosquitoes. In part 2, KAF156 was administered as single doses of 800, 300, 100, 50, or 20 mg 21 hours post-CHMI. All participants received atovaquone/proguanil treatment if blood-stage infection was detected or on day 29. For each cohort, 7–14 subjects were enrolled to KAF156 treatment and up to 4 subjects to placebo. Results KAF156 at all dose levels was safe and well tolerated. Two serious adverse events were reported—both resolved without sequelae and neither was considered related to KAF156. In part 1, all participants treated with KAF156 and none of those randomized to placebo were protected against malaria infection. In part 2, all participants treated with placebo or 20 mg KAF156 developed malaria infection. In contrast, 50 mg KAF156 protected 3 of 14 participants from infection, and doses of 800, 300, and 100 mg KAF156 protected all subjects against infection. An exposure–response analysis suggested that a 24-hour postdose concentration of KAF156 of 21.5 ng/mL (90% confidence interval, 17.66–25.32 ng/mL) would ensure a 95% chance of protection from malaria parasite infection. Conclusions KAF156 was safe and well tolerated and demonstrated high levels of pre- and post-CHMI protective efficacy. Clinical Trials Registration clinicaltrials.gov; NCT04072302 (https://clinicaltrials.gov/ct2/show/NCT04072302).


Pharmaceutics ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 989
Author(s):  
Hae-Ji Kang ◽  
Ki-Back Chu ◽  
Min-Ju Kim ◽  
Hyunwoo Park ◽  
Hui Jin ◽  
...  

Successful vaccines against specific pathogens often require multiple immunizations and adjuvant usage. Yet, assessing the protective efficacy of different immunization regimens with adjuvanted Toxoplasma gondii vaccines remains elusive. In this study, we investigated the vaccine efficacy induced by CpG-ODN-adjuvanted T. gondii virus-like particles (VLPs) after challenge infection with T. gondii (ME49) in mice (BALB/c) upon one, two, and three immunizations. Immunization with adjuvanted T. gondii VLPs induced higher levels of T. gondii-specific IgG and/or IgA antibody responses, germinal center (GC) B cells, total B cells, and CD4+ and CD8+ T cells compared with unadjuvanted VLPs. Increasing the number of immunizations was strongly correlated with enhanced protective immunity against T. gondii in mice, with the highest protection being demonstrated in mice thrice-immunized with either adjuvanted T. gondii VLPs or VLPs alone. Notably, lesser bodyweight reductions and cerebral cyst counts were observed in mice receiving multiple immunizations with the adjuvanted VLPs, thereby confirming the effectiveness of adjuvanted boost immunizations. These results demonstrated that multiple immunizations with T. gondii VLPs is an effective approach, and the CpG-ODN can be developed as an effective adjuvant for T. gondii VLP vaccines.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 1676-1676
Author(s):  
Samuel Kirimunda ◽  
Tobias Kinyera ◽  
Martin Ogwang ◽  
Steven J Reynolds ◽  
Moses Joloba ◽  
...  

Abstract Introduction: Infection with Plasmodium falciparum (Pf) malaria is widely accepted as a risk factor for endemic Burkitt lymphoma (eBL), but whether children with eBL are more likely to have detectable blood-stage Pfmalaria parasites and/or report a history of malaria morbidity compared to location-matched control children without eBL is unknown. We investigated this hypothesis in children with eBL (cases) compared to location-matched children without eBL (controls) from the National Cancer Institute (NCI)-sponsored EMBLEM Study. Methods: Cases were children with eBL aged 0-15 years presenting to two hospitals in northern Uganda from 11/2010 to 07/2014 with histologically proven, untreated eBL. Controls were children with similar malaria exposure in the region, including children attending village health centers for minor complaints (pilot health-center controls [PHCs]), at home in 12 randomly selected villages (pilot population controls [PPCs]),and at home in 88 randomly selected villages with matching for the age- and sex-distribution of eBL cases (matched population controls [MPCs]). Cases and controls provided a venous blood sample and questionnaire information on exposure to Pf malaria parasites (mosquito bed net use, insecticide sprays, proximity to a river/swamp, history of treatment for malaria). Blood-stage malaria was evaluated microscopically with giemsa-stained thin and thick blood films and with a commercially available histidine-rich protein (HRPII) antigen-based rapid diagnostic test. The log of thick-film malaria parasite count in cases and controls was compared using the Students t-test. Associations were evaluated by calculating odds ratios (ORs) and 95% confidence intervals (95% CIs) using unconditional logistic regression adjusting for sex, age, ownership/ use of mosquito bed net, and in- or out-patient treatment for malaria. Results:We studied 280 eBL cases (61% male, mean + SD age 7.9 + 3.4 years) and 1619 controls including 171 PHCs (37% male, mean + SD age 7.3 + 4.0 years), 1005 PPCs (48% male, mean + SD age 7.0 + 4.1 years) and 443 MPCs (56% male, mean + SD age 7.5 + 3.3 years). Overall, eBL cases were less likely to own a mosquito bed net than controls (46% versus 67% - 79% in controls, p<0.0001), but among those who owned a mosquito bed net, eBL cases were more likely to have used it the previous night (42% versus 21% - 31% in controls, p<0.0001). Blood-stage malaria infection was detected less frequently in cases compared to controls (Figure 1). In adjusted results, eBL cases were less likely to have current blood-stage malaria infection based on the thin film (OR 0.42 [95% CI 0.26-0.67], p<0.0001) or thick film (OR 0.55 [95% CI 0.38-0.80], p=0.001) and less likely to have had recent infection based on the HRPII rapid diagnostic test (OR 0.31 [95% CI 0.22-0.44], p<0.0001) using all controls combined, with similar results using separate control groups (OR 0.28 – 0.60). Blood-stage malaria parasite count was 0.88 log lower in parasitemic eBL cases than controls (2.24 log versus 3.12 log, p=0.0003). With all controls combined and adjusting for HRPII antigen, the risk of eBL was inversely associated with female sex (OR 0.65 [95% CI 0.46-0.90], p=0.011), ownership of mosquito bed net (OR 0.03 [95% CI 0.01-0.07], p<0.0001), and any inpatient admission for severe malaria (OR 0.56 [95% CI 0.39-0.80], p=0.001) or outpatient treatment for moderate malaria (OR 0.47 [95% CI 0.32-0.69], p<0.0001). The risk of eBL was directly associated with older age (OR 3.1 [95% CI 1.9-5.00] and OR 2.6 [95% CI 1.60-4.40], for 5-9 and 10-15 years versus 0-4 years) and not sleeping under a mosquito net the previous night (OR 10.9 [95% CI 4.34-27.3], p<0.0001). Socioeconomics, spraying insecticides, and proximity to river/swamp did not influence the results. Conclusions: Cases of eBL were unlikely to have Pf malaria parasitemia despite high exposure to mosquitoes and low ownership of bed nets. These results reject the hypothesis that eBL is associated with current or recent blood-stage Pf malaria. They support an alternative hypothesis that children with eBL have superior immunological control of blood-stage infection (Pf elite controller phenotype) and that eBL might be an accident of robust immunological control of blood-stage malaria infection. Further studies are needed to characterize the molecular spectrum of Pf parasites and other mechanisms that drive eBL genesis. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.


2019 ◽  
Vol 18 (23) ◽  
pp. 2008-2021 ◽  
Author(s):  
Snigdha Singh ◽  
Neha Sharma ◽  
Charu Upadhyay ◽  
Sumit Kumar ◽  
Brijesh Rathi ◽  
...  

Malaria is a lethal disease causing devastating global impact by killing more than 8,00,000 individuals yearly. A noticeable decline in malaria related deaths can be attributed to the most reliable treatment, ACTs against P. falciparum. However, the cumulative resistance of the malaria parasite against ACTs is a global threat to control the disease and, therefore the new effective therapeutics are urgently needed, including new treatment approaches. Majority of the antimalarial drugs target BS malarial infection. Currently, scientists are eager to explore the drugs with potency against not only BS but other life stages such as sexual and asexual stages of the malaria parasite. Liver Stage is considered as one of the important drug targets as it always leads to BS and the infection can be cured at this stage before it enters into the Blood Stage. However, a limited number of compounds are reported effective against LS malaria infection probably due to scarcity of in vitro LS culture methods and clinical possibilities. This mini review covers a range of chemical compounds showing efficacy against BS and LS of the malaria parasite’s life cycle collectively (i.e. dual stage activity). These scaffolds targeting dual stages are essential for the eradication of malaria and to evade resistance.


Sign in / Sign up

Export Citation Format

Share Document